We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DMAA:NASDAQDrugs Made In America Acquisition Corp. Analysis

Data as of 2026-09-19 - not real-time

$10.84

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

At $10.84, Drugs Made In America Acquisition Corp. shows a bullish moving-average alignment, with shorter averages sitting above longer ones. Over a rolling month the price has gained 1.2%. Momentum indicators put RSI at 85.5 (overbought) with MACD reading bullish. Price has been bracketed by support at $10.73 and resistance at $10.85.
On valuation the read is overvalued — earnings multiple of 60.2 versus a 15.8 sector average, above the peer group.
On a 1-10 scale the risk profile lands at 4 — moderate. With 30-day volatility of 1.5% and a beta of 0.00, position sizing matters here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 3/10 conviction over the longer horizon.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • RSI at 85.5 signals overbought conditions
  • Trading above the 200-day average of 10.56

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • RSI at 85.5 signals overbought conditions
  • P/E of 60.2 versus sector average of 15.8

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • P/E of 60.2 versus sector average of 15.8
  • Thin trading liquidity raises execution risk
  • Short-term moving averages stacked above long-term ones

Key Metrics & Analysis

Financial Health

P/E Ratio60.2
P/B Ratio-35.5
Op. Cash Flow$-517145
Industry P/E15.8

Technical Analysis

TrendBullish
RSI85.5
Support$10.73
Resistance$10.85
MA 20$10.78
MA 50$10.73
MA 200$10.56
MACDBullish
VolumeIncreasing
Fear & Greed Index94.98

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.00
Volatility1.52%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.